31.15

2.74% 0.83

Pre-market: 31.99 0.84 +2.70%

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $31.15, with a volume of 2.18M. It is up +2.74% in the last 24 hours and up +33.63% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Previous Close:

$30.32

Open:

$30.45

24h Volume:

2.18M

Relative Volume:

0.61

Market Cap:

$4.90B

Revenue:

$264.79M

Net Income/Loss:

$-14.36M

P/E Ratio:

-111.25

EPS:

-0.28

Net Cash Flow:

$67.82M

1W Performance:

-10.74%

1M Performance:

+33.63%

6M Performance:

+89.02%

1Y Performance:

+142.98%

1-Day Range:

$29.91

$32.00

1-Week Range:

$28.59

$36.50

52-Week Range:

$12.25

$36.50

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

264

Twitter

@TGTherapeutics

Next Earnings Date

2024-11-04

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX	31.15	4.90B	264.79M	-14.36M	67.82M	-0.28
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

06:02 AM

TG Therapeutics Ranked Number One Fastest-Growing Company - GlobeNewswire

06:02 AM

06:00 AM

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - Yahoo Finance

06:00 AM

Nov 20, 2024

Oppenheimer & Co. Inc. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Nov 20, 2024

Nov 18, 2024

State of New Jersey Common Pension Fund D Decreases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Nov 18, 2024

Nov 15, 2024

When (TGTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024

Entropy Technologies LP Purchases Shares of 31,200 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Nov 15, 2024

Principal Financial Group Inc. Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Nov 15, 2024

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Amalgamated Bank - MarketBeat

Nov 15, 2024

Nov 13, 2024

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Los Angeles Capital Management LLC - MarketBeat

Nov 13, 2024

Nov 12, 2024

Insider Sale: Director Laurence Charney Sells 25,000 Shares of T - GuruFocus.com

Nov 12, 2024

Insider Sale: Director Sagar Lonial Sells 5,000 Shares of TG The - GuruFocus.com

Nov 12, 2024

Nov 10, 2024

New York State Teachers Retirement System Invests $1 Million in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Nov 10, 2024

Nov 09, 2024

Don't Ignore The Insider Selling In TG Therapeutics - Simply Wall St

Nov 09, 2024

Nov 08, 2024

TG Therapeutics stock hits 52-week high at $28.43 - Investing.com India

Nov 08, 2024

TG Therapeutics stock hits 52-week high at $28.43 By Investing.com - Investing.com Canada

Nov 08, 2024

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking - Simply Wall St

Nov 07, 2024

TG Therapeutics, Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance

Nov 07, 2024

FY2024 EPS Estimates for TG Therapeutics Lowered by Analyst - MarketBeat

Nov 07, 2024

Nov 06, 2024

HC Wainwright Boosts Earnings Estimates for TG Therapeutics - MarketBeat

Nov 06, 2024

Nov 05, 2024